CHRNB1 sirna

CHRNB1 siRNA (Human)

Cat. Num. AAA8222750

• Gene Names: CHRNB1; ACHRB; CHRNB; CMS1D; CMS2A; CMS2C; SCCMS
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: CHRNB1; CHRNB1 siRNA (Human); ACHRB; CHRNB; Acetylcholine receptor subunit beta; CHRNB1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: CHRNB1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 501

• Applicable Applications for CHRNB1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CHRNB1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for CHRNB1 sirna

siRNA to inhibit CHRNB1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 41327726
• NCBI GeneID: 1140
• NCBI Accession #: NP_000738.2
• NCBI GenBank Nucleotide #: NM_000747.2
• UniProt Accession #: P11230; Q8IZ46; Q96FB8; B7Z5H1
• Molecular Weight: 49,083 Da
• NCBI Official Full Name: acetylcholine receptor subunit beta
• NCBI Official Synonym Full Names: cholinergic receptor, nicotinic, beta 1 (muscle)
• NCBI Official Symbol: CHRNB1
• NCBI Official Synonym Symbols: ACHRB; CHRNB; CMS1D; CMS2A; CMS2C; SCCMS
• NCBI Protein Information: acetylcholine receptor subunit beta
• UniProt Protein Name: Acetylcholine receptor subunit beta
• Protein Family: Acetylcholine receptor
• UniProt Gene Name: CHRNB1
• UniProt Synonym Gene Names: ACHRB; CHRNB
• UniProt Entry Name: ACHB_HUMAN

NCBI Description

The muscle acetylcholine receptor is composed of five subunits: two alpha subunits and one beta, one gamma, and one delta subunit. This gene encodes the beta subunit of the acetylcholine receptor. The acetylcholine receptor changes conformation upon acetylcholine binding leading to the opening of an ion-conducting channel across the plasma membrane. Mutations in this gene are associated with slow-channel congenital myasthenic syndrome. [provided by RefSeq, Jul 2008]

Uniprot Description

nAChRB1: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. Defects in CHRNB1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS). SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes. Defects in CHRNB1 are a cause of congenital myasthenic syndrome with acetylcholine receptor deficiency (CMS-ACHRD). CMS-ACHRD is a postsynaptic congenital myasthenic syndrome. Mutations underlying AChR deficiency cause a 'loss of function' and show recessive inheritance. Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta- 1/CHRNB1 sub-subfamily.

Protein type: Channel, ligand-gated; Membrane protein, multi-pass; Channel, cation; Membrane protein, integral

Chromosomal Location of Human Ortholog: 17p13.1

Cellular Component: nicotinic acetylcholine-gated receptor-channel complex; postsynaptic membrane; integral to plasma membrane; synapse; cell junction

Molecular Function: channel activity; acetylcholine receptor activity; acetylcholine binding; nicotinic acetylcholine-activated cation-selective channel activity; ligand-gated ion channel activity

Biological Process: skeletal muscle contraction; regulation of membrane potential; muscle contraction; neuromuscular synaptic transmission; behavioral response to nicotine; muscle fiber development; signal transduction; postsynaptic membrane organization; transmembrane transport; cation transport; synaptic transmission, cholinergic; neurological system process

Disease: Myasthenic Syndrome, Congenital, 2c, Associated With Acetylcholine Receptor Deficiency; Myasthenic Syndrome, Congenital, 2a, Slow-channel